The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Tisagenlecleucel in R/R follicular lymphoma: ELARA data
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the ELARA trial (NCT03568461). This Phase II trial assessed the efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
